[18F]DCFPyL was assessed to be a suitable alternative to [68Ga]Ga-PSMA-11 in PCa diagnosis and staging due to its similar lesion uptake rate with no increase in benign uptakes. [18F]PSMA-1007 was assessed to be less preferrable to [68Ga]Ga-PSMA-11 due to its significant number of benign bone uptakes. Although [18F]PSMA-1007 was able to detect more locoregional lesions due to its lower urinary excretions, the use of diuretics prior to the scan facilitated [68Ga]Ga-PSMA-11 to achieve a similar local lesion detection rate in comparison to [18F]PSMA-1007. Overall, there was not enough evidence in differentiating [18F]DCFPyL and [68Ga]Ga-PSMA-11 in their clinical impacts. The decision to use [18F]DCFPyL or [68Ga]Ga-PSMA-11 is largely based on infrastructure available at the individual health service.
https://www.nature.com/articles/s41391-023-00755-2
- Forums
- ASX - By Stock
- TLX
- Understanding Telix
Understanding Telix, page-1203
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.81 |
Change
0.490(2.54%) |
Mkt cap ! $6.629B |
Open | High | Low | Value | Volume |
$19.49 | $19.81 | $19.28 | $27.96M | 1.430M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 150 | $19.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.81 | 10432 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 150 | 19.800 |
2 | 1178 | 19.580 |
1 | 17001 | 19.570 |
1 | 1000 | 19.560 |
1 | 3649 | 19.550 |
Price($) | Vol. | No. |
---|---|---|
19.810 | 10432 | 1 |
19.820 | 3649 | 1 |
19.840 | 1956 | 1 |
19.860 | 7695 | 2 |
19.880 | 770 | 2 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |